Revvity Inc. logo

Revvity Inc.(RVTY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
SELL
SELL for 3 days
PROFIT SINCE LAST BUY
+50.07% ▲
LAST CLOSE
$152.43
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RVTY

11/18/2026: RVTY (3-star) is a SELL. SELL for 3 days. Simulated Profits (50.07%). Updated daily EoD!

Revvity Inc. is a specialized life sciences and diagnostics company that provides analytical instruments, software, and newborn screening solutions. The company benefits from strong recurring revenue streams in diagnostics and a streamlined portfolio following its strategic divestiture. Its primary growth opportunity lies in precision medicine expansion and lab informatics adoption, countered by biopharma funding volatility and intense competition from larger conglomerates. The stock suits growth-oriented healthcare investors who should closely monitor academic research spending trends and integration progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers steady mid-single-digit organic growth with upside from precision medicine, though lacking hyper-growth tech characteristics.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal (Strong Buy / Buy) reflecting active sectoral tailwinds.
Value investorMixed fitValuation reflects stable life science asset quality, offering reasonable multiples without deep-value bargain pricing.
Dividend investorWeak fitProvides modest dividend yields oriented more toward capital reinvestment than high-income distribution.
Low-risk investorMixed fitDefensive healthcare qualities are tempered by exposure to biopharma R&D spending volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumStock price movements reflect broader life science sector sentiment and periodic shifts in biopharma funding.
Valuation riskMediumMultiples depend heavily on sustained execution in high-margin diagnostic and reagent segments.
Competition risk (Thermo Fisher and Danaher competition)Medium / highLarger industry peers possess extensive distribution networks and capital resources that challenge smaller competitors.
Business qualityStrongHigh recurring revenue from consumables and sticky diagnostic placements underpin structural franchise strength.
Dividend incomeLowPayouts are conservative, making the stock unsuited for income-focused portfolios.
Execution riskMediumManagement must successfully integrate past major acquisitions like BioLegend while optimizing post-divestiture cost structures.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 16.50B USD
Price to earnings Ratio 66.27
1Y Target Price 171.4
Price to earnings Ratio 66.27
1Y Target Price 171.4
Volume (30-day avg) 1.7M shares
Beta 1.09
52 Weeks Range 81.13 - 171.74
Updated Date 11/17/2026
52 Weeks Range 81.13 - 171.74
Updated Date 11/17/2026
Dividends yield (FY) 0.19%
Basic EPS (TTM) 2.23

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
50.0%
Active BUY / eligible
7 / 14
30-Day BUY Count Change
-2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Hockey-Stick Growth
PRICE PATH

Hockey-Stick Growth

The stock demonstrates a Hockey-Stick Growth price path pattern.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 18.94%
Avg. Invested days 52
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RVTY receives a 3-star rating, supported by solid unit economics, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
RVTY has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 17.8%) is partially offset by negative earnings growth (-18.3%), moderate revenue growth (+3.7%), soft profitability (net margin 8.5%).

Financial Health Rating

★★★★★
RVTY's financial health is supported by solid cash strength, including free-cash-flow generation (17.8% of revenue). Liquidity is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is RVTY's strongest growth driver at +3.7% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-18.3%, negative) and free-cash-flow growth (-6.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 102.7% and approximately 91.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.26%, which materially reduces the ownership score.

Top 5 Institutional Investors

T. Rowe Price Investment Management,Inc. 16.36%
Jupiter Topco LLC 7.74%
EdgePoint Investment 7.65%
BlackRock Inc 6.86%
Vanguard Capital Management, LLC 6.54%

Unit Economics (Per $1K Revenue)

★★★★★
RVTY generates approximately $531 of gross profit, $125 of operating income, and $178 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and strong cash conversion support the rating, although capital efficiency remains weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 9.62%

Quantitative Style Profile

★★★★★
RVTY has a large-cap, liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Large / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Life SciencesReagents, assay kits, cellular imaging systems, and research informatics software used in drug discovery.Generates steady research-driven revenues from global pharmaceutical and academic laboratories.
DiagnosticsNewborn screening instruments, immunodiagnostic tests, and molecular assay solutions.Provides sticky, recurring consumable sales driven by essential routine healthcare screening procedures.
Geographic ExposureCommercial operations spanning North America, Europe, and Asia-Pacific.International diversification cushions against localized economic downturns but exposes results to foreign exchange risks.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When Before Market
Estimate 1.29
Actual 1.38

Profitability

Profit Margin 8.61%
Operating Margin (TTM) 16.66%

Management Effectiveness

Return on Assets (TTM) 2.59%
Return on Equity (TTM) 3.45%

Valuation

Trailing PE 66.27
Forward PE 24.88
Enterprise Value 18.79B
Price to Sales(TTM) 5.61
Enterprise Value 18.79B
Price to Sales(TTM) 5.61
Enterprise Value to Revenue 6.39
Enterprise Value to EBITDA 23.85
Shares Outstanding 111.64M
Shares Floating 102.54M
Shares Outstanding 111.64M
Shares Floating 102.54M
Percent Insiders 0.26
Percent Institutions 102.71

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.